Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 3/20 | 0.51 |
| ▸ | SKP1 | P63208 | 3/20 | 0.51 |
| ▸ | SKP2 | Q13309 | 3/20 | 0.51 |
| ▸ | ATR | Q13535 | 2/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 6/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17111652 | 0.82 | MAPK1 (0.46) | ATRMAPKAPK2MAPK1 | |
| SCHEMBL17133442 | 0.79 | CKS1B (0.51) | CKS1BSKP1SKP2ATRMAPKAPK2 | |
| SCHEMBL18137292 | 0.77 | CKS1B (0.43) | CKS1BSKP1SKP2ATRKDM4A | |
| SCHEMBL31540432 | 0.77 | HDAC1 (0.48) | CKS1BSKP1SKP2KDM4A | |
| SCHEMBL25551904 | 0.74 | CKS1B (0.51) | CKS1BSKP1SKP2KDM4A | |
| SCHEMBL26616783 | 0.74 | TRPV3 (0.48) | CKS1BSKP1SKP2KDM4A | |
| SCHEMBL31431219 | 0.73 | PDPK1 (0.43) | MAPKAPK2KDM4A | |
| SCHEMBL25551937 | 0.73 | CKS1B (0.49) | CKS1BSKP1SKP2KDM4A | |
| SCHEMBL30036979 | 0.73 | CKS1B (0.49) | CKS1BSKP1SKP2KDM4A | |
| SCHEMBL3633138 | 0.73 | KDM4A (0.54) | CKS1BSKP1SKP2MAPK1KDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3122346-B1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME (US) | 2020-07-15 | — | — | EP | disclosed |
| US-9815846-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815846-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170114071-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170114071-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-04-27 | — | — | US | disclosed |
| WO-2015148344-A2 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114071-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | NGFR, NGF, NTRK1 | CKS1B 260/4885SKP1 602/4885SKP2 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.